Telix is commercialising its therapeutic and diagnostic radiopharmaceuticals. Its share price has more than doubled in 2024, and the company now has a market capitalisation of almost $6.4 billion.
Telix completes significant raise that could be used for acquisitions
July 25, 2024 Latest NewsBioPharmaLatest Video
New Stories
-
New research uncovers Australian women are often reluctant to openly talk about menopause
October 18, 2024 - - Latest News -
The danger of this outlier is reflected in the disconnect with another policy process
October 18, 2024 - - Latest News -
Pharmac seeking bids from suppliers of COVID-19 vaccines
October 17, 2024 - - Latest News -
Auditor General launches audit of the procurement of onshore vaccine manufacturing facilities
October 17, 2024 - - Latest News -
This has happened before and the response should be the same. No.
October 17, 2024 - - Latest News -
Vitalis and Servita partner to lead healthcare digital transformation in Queensland
October 17, 2024 - - Latest News -
Commercial Eyes signs new AI-focused service agreement with Opyl
October 17, 2024 - - Latest News